Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024 Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024 Q2 …

… the second quarter and first half ended 30 June 2025. … the first half of 2025. We are seeing increasing revenues from … period. This change in profitability reflects the combined effect … . –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma …

… The multinational pharmaceutical group said that revenues grew by 6 … priorities" during the first half in 2025. A Hikma … September 2024. During the first half, we received FDA … licensing agreement with pharmaand GmbH (pharma&) to commercialise …

… reported second quarter and first half 2025 financial results and … entered into a specialty pharmacy agreement with Biologics … the first half of 2024.  Revenue consists of product revenue from … revenue from product sales, and we may not become profitable …

… Interim Report for the First Half Ended June 30, 2025 … Genmab. Financial Performance First Half of 2025 Revenue was $1, … Pharma AG (Novartis), respectively, and higher EPKINLY net product sales. Royalty revenue … as well as profit-sharing amounts payable …

… first dedicated cancer pharmacy was also inaugurated, … performance significantly strengthened the first-half outcome, underscoring Burjeel … benefits, enhancing both revenue and profitability. We continue … H1’25. Inpatient volumes rose 14.6% over the first half …

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) was the biggest faller on the FTSE 100 on Thursday morning after the drugmaker's interim results showed a 7% fall in core operating profit. However, the decline in profits was not as bad as analysts …

… Pharmaceuticals. “Our strong commercial execution helped us deliver an impressive 108% revenue … the first half of … Profit: Gross profit … Related Costs     Non-GAAP   Revenues:                                                 Licensing revenue   $ —     $ — …

… decision in the first half of 2026. … Pharmaceuticals Crinetics Pharmaceuticals is a clinical-stage pharmaceutical … . CRINETICS PHARMACEUTICALS, INC.CRINETICS PHARMACEUTICALS, INC. … 2024     2025     2024                             Revenues   $ 1,031     $ 399 …

… Remed Pharmaceuticals recorded accelerated sales in the first half of … has successfully maintained strong profitability and effective cost controls … and development oriented pharmaceutical company. To ensure … ownership of Remed Pharmaceuticals in pursuit of …